690 related articles for article (PubMed ID: 20116628)
21. Etravirine.
Knoll BM; Vento S; Temesgen Z
Drugs Today (Barc); 2008 Jan; 44(1):23-33. PubMed ID: 18301801
[TBL] [Abstract][Full Text] [Related]
22. Etravirine.
Deeks ED; Keating GM
Drugs; 2008; 68(16):2357-72. PubMed ID: 18973398
[TBL] [Abstract][Full Text] [Related]
23. [Etravirine: genetic barrier and resistance development].
Llibre JM; Santos JR; Clotet B
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():32-9. PubMed ID: 20116626
[TBL] [Abstract][Full Text] [Related]
24. Etravirine for the treatment of HIV/AIDS.
Schrijvers R
Expert Opin Pharmacother; 2013 Jun; 14(8):1087-96. PubMed ID: 23560740
[TBL] [Abstract][Full Text] [Related]
25. Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300.
Hull MW; Montaner JS
Expert Opin Pharmacother; 2010 Jun; 11(8):1433-7. PubMed ID: 20367279
[TBL] [Abstract][Full Text] [Related]
26. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.
Waters L; Fisher M; Winston A; Higgs C; Hadley W; Garvey L; Mandalia S; Perry N; Nicola M; Nelson M
AIDS; 2011 Jan; 25(1):65-71. PubMed ID: 21099666
[TBL] [Abstract][Full Text] [Related]
27. [Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors].
Pulido F; Fiorante S
Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():13-8. PubMed ID: 19195433
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.
Katlama C; Clotet B; Mills A; Trottier B; Molina JM; Grinsztejn B; Towner W; Haubrich R; Nijs S; Vingerhoets J; Woodfall B; Witek J
Antivir Ther; 2010; 15(7):1045-52. PubMed ID: 21041921
[TBL] [Abstract][Full Text] [Related]
29. Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection.
Croxtall JD
Drugs; 2012 Apr; 72(6):847-69. PubMed ID: 22512366
[TBL] [Abstract][Full Text] [Related]
30. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor.
Johnson LB; Saravolatz LD
Clin Infect Dis; 2009 Apr; 48(8):1123-8. PubMed ID: 19275497
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
Madruga JV; Cahn P; Grinsztejn B; Haubrich R; Lalezari J; Mills A; Pialoux G; Wilkin T; Peeters M; Vingerhoets J; de Smedt G; Leopold L; Trefiglio R; Woodfall B;
Lancet; 2007 Jul; 370(9581):29-38. PubMed ID: 17617270
[TBL] [Abstract][Full Text] [Related]
32. [Resistance profile of rilpivirine].
Imaz A; García F; di Yacovo S; Llibre JM
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():36-43. PubMed ID: 24252532
[TBL] [Abstract][Full Text] [Related]
33. Etravirine(Intelence) for HIV infection.
Med Lett Drugs Ther; 2008 Jun; 50(1288):47-8. PubMed ID: 18551091
[No Abstract] [Full Text] [Related]
34. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
35. [Potential role of rilpivirine in simplification regimens].
Casado JL; Moreno S
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():30-5. PubMed ID: 24252531
[TBL] [Abstract][Full Text] [Related]
36. [Introduction. Etravirine: a new standard of potency and safety among non-nucleoside analogues].
Domingo P
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():1. PubMed ID: 20116620
[No Abstract] [Full Text] [Related]
37. Therapeutic drug monitoring and the inhibitory quotient of antiretroviral drugs: can they be applied to the current situation?
Ribera E; López-Cortés LF; Soriano V; Casado JL; Mallolas J
Enferm Infecc Microbiol Clin; 2005 Jul; 23 Suppl 2():41-67. PubMed ID: 16373004
[TBL] [Abstract][Full Text] [Related]
38. Etravirine: a guide to its use in treatment-experienced pediatric patients with HIV-1 infection in the US.
Lyseng-Williamson KA
Paediatr Drugs; 2012 Oct; 14(5):345-50. PubMed ID: 22897163
[TBL] [Abstract][Full Text] [Related]
39. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
Arribas JR
Curr Opin HIV AIDS; 2009 Nov; 4(6):507-12. PubMed ID: 20048718
[TBL] [Abstract][Full Text] [Related]
40. [Clinical data I. Clinical experience with tenofovir in combination with nonnucleoside analogue transcriptase inhibitors].
Bernardino de la Serna JI; Mora Rillo M; Arribas López JR
Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():7-12. PubMed ID: 19195432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
